Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 22.06% is 55% below its 5-year average of 48.60%, near the low end of its 5-year range (18.87%–176.89%).
As of the fiscal period ended Wednesday, December 31, 2025. 8.80% above its 12-month average of 20.27%.
Annual fiscal-year return on assets; no daily interpolation.
RETURN ON ASSETS (ROA)
22.06%
RETURN ON ASSETS (ROA) AVG TTM
20.27%
RETURN ON ASSETS (ROA) AVG 3Y
22.54%
RETURN ON ASSETS (ROA) AVG 5Y
48.60%
RETURN ON ASSETS (ROA) AVG 10Y
58.82%
RETURN ON ASSETS (ROA) AVG 15Y
29.74%
RETURN ON ASSETS (ROA) AVG 20Y
26.39%
CURRENT VS TTM AVG
+8.80%
CURRENT VS 3Y AVG
-2.14%
CURRENT VS 5Y AVG
-54.61%
CURRENT VS 10Y AVG
-62.50%
CURRENT VS 15Y AVG
-25.83%
CURRENT VS 20Y AVG
-16.40%
SECTOR MEDIAN · HEALTHCARE
4.97%
median of 79 covered companies
CURRENT VS SECTOR MEDIAN
+343.86%
vs the sector median at left
Novo Nordisk A/S
Market Cap
$210.50B
Return on Assets (ROA)
22.06%
TTM Avg
20.27%
3Y Avg
22.54%
5Y Avg
48.60%
Market Cap
$209.79B
Return on Assets (ROA)
6.17%
TTM Avg
6.31%
3Y Avg
6.46%
5Y Avg
7.20%
Market Cap
$182.21B
Return on Assets (ROA)
4.97%
TTM Avg
11.99%
3Y Avg
10.28%
5Y Avg
9.45%
Market Cap
$243.87B
Return on Assets (ROA)
9.03%
TTM Avg
7.88%
3Y Avg
6.26%
5Y Avg
4.99%
Market Cap
$162.38B
Return on Assets (ROA)
16.38%
TTM Avg
7.62%
3Y Avg
7.90%
5Y Avg
6.83%
Market Cap
$136.91B
Return on Assets (ROA)
4.33%
TTM Avg
4.68%
3Y Avg
5.89%
5Y Avg
6.01%
Market Cap
$132.22B
Return on Assets (ROA)
1.16%
TTM Avg
1.25%
3Y Avg
1.93%
5Y Avg
2.38%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Novo Nordisk A/S (NVO) | $210.50B | 22.06% | 20.27% | 22.54% | 48.60% |
| Thermo Fisher Scientific Inc. (TMO)vs › | $209.79B | 6.17% | 6.31% | 6.46% | 7.20% |
| Amgen Inc. (AMGN)vs › | $205.47B | 8.43% | 6.48% | 7.48% | 8.52% |
| Abbott Laboratories (ABT)vs › | $182.21B | 4.97% | 11.99% | 10.28% | 9.45% |
| AstraZeneca PLC (AZN)vs › | $243.87B | 9.03% | 7.88% | 6.26% | 4.99% |
| Gilead Sciences, Inc. (GILD)vs › | $162.38B | 16.38% | 7.62% | 7.90% | 6.83% |
| Pfizer Inc. (PFE)vs › | $141.72B | 3.61% | 3.75% | 6.08% | 7.08% |
| Danaher Corporation (DHR)vs › | $136.91B | 4.33% | 4.68% | 5.89% | 6.01% |
| CVS Health Corp. (CVS)vs › | $132.22B | 1.16% | 1.25% | 1.93% | 2.38% |
| Bristol-Myers Squibb Company (BMY)vs › | $132.06B | 10.59% | -0.92% | 3.28% | 1.99% |
ROA
22.1%
ROE
60.7%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 18.87% |
| 2024-12-31 | 21.68% |
| 2023-12-31 | 26.61% |
| 2022-12-31 | 23.01% |
| 2021-12-31 | 24.55% |
| 2020-12-31 | 176.89% |
| 2019-12-31 | 206.43% |
| 2018-12-31 | 34.87% |
| 2017-12-31 | 37.25% |
| 2016-12-31 | 38.88% |
| 2015-12-31 | 37.97% |
| 2014-12-31 | 34.36% |
| 2013-12-31 | 35.80% |
| 2012-12-31 | 32.64% |
| 2011-12-31 | 26.43% |
| 2010-12-31 | 23.46% |
| 2009-12-31 | 19.67% |
| 2008-12-31 | 19.06% |
| 2007-12-31 | 17.86% |
| 2006-12-31 | 14.44% |
| 2005-12-31 | 13.98% |
| 2004-12-31 | 13.39% |
| 2003-12-31 | 14.13% |
| 2002-12-31 | 13.01% |
| 2001-12-31 | 13.36% |
| 2000-12-31 | 12.55% |
| 1999-12-31 | 7.79% |
| 1998-12-31 | 8.83% |
| 1997-12-31 | 8.64% |
| 1996-12-31 | 8.56% |
